The Generic Pharmaceutical Association and the Pharmaceutical Care Management Association opposed efforts to lobby states for restrictions on biosimilars before the FDA has established a pathway for their approval. PhRMA has said that patient safety should be the top priority and that "given the limits of current scientific knowledge and for reasons of patient safety, we cannot envision a biosimilar product or class of products for which comparative clinical studies would be unnecessary for approval."

Full Story:
PharmaTimes (U.K.)

Related Summaries